Altiratinib (DCC-2701) is a potent inhibitor of TRK, Met (C-MET), TIE2, and VEGFR2 kinases with IC50 of 0.9 nM, 4.6 nM, and 0.8 nM for TRKA, B, and c, respectively. It inhibits Met (c-Met) and Met (c-Met) mutants in the IC50 range of 0.3-6 nM.

 

Brand: BCM

 

Target: VEGFR; Tie-2; FLT; Trk receptor; c-Met/HGFR

 

Signaling Pathways: Angiogenesis; Tyrosine Kinase/Adaptors

 

Boiling Point: 763.5±60.0 °C(Predicted)

 

pKa: 12.09±0.70(Predicted)

 

Solubility: Soluble in DMSO. Insoluble in Water; Insoluble in Ethanol.

 

GHS: GHS07

 

Isomeric SMILES: C1CC1C(=O)NC2=NC=CC(=C2)OC3=C(C=C(C(=C3)F)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F)F  

 

InChIKey: GNNDEPIMDAZHRQ-UHFFFAOYSA-N  

 

InChI: InChI=1S/C26H21F3N4O4/c27-15-3-5-16(6-4-15)31-24(35)26(8-9-26)25(36)32-20-12-19(29)21(13-18(20)28)37-17-7-10-30-22(11-17)33-23(34)14-1-2-14/h3-7,10-14H,1-2,8-9H2,(H,31,35)(H,32,36)(H,30,33,34)

 

Attribute
[Chem Name]	1-N'-[4-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-2,5-difluorophenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
[Synonym]	Altiratinib; DCC-2701
[CAS No.]	1345847-93-9
[EINECS]	1592732-453-0
[MDL No.]	MFCD28900672
[Formula]	C26H21F3N4O4
[Molecular]	510.46
[Form]	Solid Powder
[Storage]	Sealed in dry, 2-8°C

Goods Tag